Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 95)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Racepinephrine |
Approved |
Phase 4 |
|
329-65-7 |
838 |
Synonyms:
(+-)-Adrenaline
(+-)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
Bird brand OF racepinefrine hydrochloride
DL-Adrenaline
Epinephrine hydrochloride, racemic mixture
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Hydrochloride, racepinephrine
Micronefrin
|
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Vaponefrin
|
|
2 |
|
Dopexamine |
Approved, Investigational |
Phase 4 |
|
86197-47-9 |
55483 |
Synonyms:
Dopacard
Dopexamine dihydrobromide
Dopexamine dihydrochloride
|
Dopexamine hydrochloride
FPL 60278
|
|
3 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260 |
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(−)-arterenol
(-)-Arterenol
(-)-Arterenol free base
(−)-noradrenaline
(-)-Noradrenaline
(-)-NORADRENALINE
(−)-norepinephrine
(-)-Norepinephrine
(+)-Palmitoylcarnitine
(2S)-2-{[(1S)-5-amino-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]-C-hydroxycarbonimidoyl}pentyl]amino}-4-phenylbutanoate
(3R)-3-(Hexadecanoyloxy)-4-(trimethylazaniumyl)butanoate
(3R)-3-(Hexadecanoyloxy)-4-(trimethylazaniumyl)butanoic acid
(3R)-3-Palmitoyloxy-4-(trimethylammonio)butanoate
(3R)-3-Palmitoyloxy-4-(trimethylammonio)butanoic acid
(3S)-3-Hexadecanoyloxy-4-(trimethylammonio)butanoate
(3S)-3-Hexadecanoyloxy-4-(trimethylammonio)butanoic acid
(3S)-3-Palmitoyloxy-4-(trimethylammonio)butanoate
(3S)-3-Palmitoyloxy-4-(trimethylammonio)butanoic acid
(R)-(−)-norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-noradrenaline
(R)-Noradrenaline
(R)-norepinephrine
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
2'-(Dihydrogen phosphate) 5'-(trihydrogen pyrophosphate) adenosine 5'-ester with 1,4-dihydro-1-b-D-ribofuranosylnicotinamide
2'-(Dihydrogen phosphate) 5'-(trihydrogen pyrophosphate) adenosine 5'-ester with 1,4-dihydro-1-beta-delta-ribofuranosylnicotinamide
2-Ketoadipate
2-Keto-adipate
2-Ketoadipic acid
2-Oxoadipate
2-Oxoadipic acid
2-oxo-Hexanedioate
2-Oxohexanedioate
2-oxo-Hexanedioic acid
2-Oxohexanedioic acid
2-Oxohexanedionic acid
3-Carboxy-N,N,N-trimethyl-2-[(1-oxohexadecyl)oxy]-1-propanaminium
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
Abbott brand OF levophed bitartrate
AC1L96ZT
Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) p'-5'-ester with 1,4-dihydro-1-beta-delta-ribofuranosyl-3-pyridinecarboxamide
Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) p'-5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
Adrenor
a-Ketoadipate
a-Ketoadipic acid
Aktamin
ALBB-006229
alpha-Ketoadipate
alpha-Ketoadipic acid
alpha-Oxoadipate
alpha-Oxoadipic acid
a-Oxoadipate
a-Oxoadipic acid
Arterenol
Aventis brand OF norepinephrine hydrochloride
beta-NADPH
beta-Nicotinamide-adenine-dinucleotide-phosphorate
beta-Nicotinamide-adenine-dinucleotide-phosphoric acid
Bitartrate, levophed
Bitartrate, noradrenaline
Bitartrate, norepinephrine
bmse000404
b-NADPH
b-Nicotinamide-adenine-dinucleotide-phosphorate
b-Nicotinamide-adenine-dinucleotide-phosphoric acid
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
Dihydrocodehydrogenase II
Dihydronicotinamide adenine dinucleotide phosphate
Dihydronicotinamide adenine dinucleotide-p
Dihydrotriphosphopyridine nucleotide reduced
DivK1c_000230
D-Palmitylcarnitine
EINECS 200-096-6
Hexadecanoylcarnitine
Hexadecanoyl-L-carnitine
Hexadecenoyl carnitine
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
Hydrochloride, norepinephrine
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L(-)-Palmitylcarnitine
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
|
L-3,4-dihydroxyphenylethanolamine
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-Arterenol
L-Carnitine palmitoyl ester
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
Levophed bitartrate
L-noradrenaline
L-Noradrenaline
L-Norepinephrine
L-NOREPINEPHRINE
L-Palmitoyl-L-carnitine
LS-42676
LT03330026
LT4
NADP-reduced
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
Nicotinamide adenine dinucleotide phosphate - reduced
Nicotinamide-adenine-dinucleotide-phosphorate
Nicotinamide-adenine-dinucleotide-phosphoric acid
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
noradrenaline
Noradrenaline
Nor-adrenaline
Noradrenaline (JP15)
Noradrenaline bitartrate
Noradrénaline tartrate renaudin
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
norepinefrina
Norepinefrina
Norepinephrin D-tartrate (1:1)
norepinephrine
Norepinephrine
Norépinéphrine
Norepinephrine (INN)
Norepinephrine [INN:JAN]
Norepinephrine bitartrate
Norepinephrine D-tartrate (1:1)
Norepinephrine hydrochloride
Norepinephrine hydrochloride, (+)-isomer
Norepinephrine hydrochloride, (+,-)-isomer
Norepinephrine l-Tartrate (1:1)
Norepinephrine L-tartrate (1:1)
Norepinephrine L-tartrate (1:1), (+,-)-isomer
Norepinephrine L-tartrate (1:1), monohydrate
Norepinephrine L-tartrate (1:1), monohydrate, (+)-isomer
Norepinephrine L-tartrate (1:2)
Norepinephrine L-tartrate, (+)-isomer
Norepinephrine Noradrenalin
Norepinephrine, (+)-isomer
Norepinephrine, (+,-)-isomer
norepinephrinum
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
Nor-epirenan
O-Hexadecanoyl-(R)-carnitine
O-Hexadecanoyl-R-carnitine
Oxoadipate
Palmitoyl D-carnitine
Palmitoyl-(-)-carnitine
Palmitoylcarnitine
Palmitoyl-L-carnitine
Palmitylcarnitine
Palmityl-L-carnitine
PDSP1_001111
PDSP2_001095
Reduced codehydrase II
Reduced coenzyme II
Reduced cozymase II
Reduced triphosphopyridine nucleotide
Renaudin brand OF norepinephrine bitartrate
Renaudin, noradrénaline tartrate
SGCUT00123
SPBio_001048
Spectrum_001009
SPECTRUM1500436
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
STK503776
Sympathin e
Sympathin E
Tartrate renaudin, noradrénaline
to_000024
Triphosphopyridine nucleotide reduced
UNII-X4W3ENH1CV
|
|
4 |
|
Dobutamine |
Approved |
Phase 4 |
|
34368-04-2 |
36811 |
Synonyms:
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-b-phenylethylamine
3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine
34368-04-2
34368-04-2 (Parent)
4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
52663-81-7 (hydrochloride)
74753-15-4
74753-15-4 (hydrobromide)
AC1L1WFF
AC1Q7AD1
Boehringer ingelheim brand OF dobutamine hydrochloride
BPBio1_000489
BRD-A78322124-003-03-3
BSPBio_000443
C06967
CHEBI:4670
CHEMBL926
CID36811
D03879
DB00841
DL-dobutamine
DL-Dobutamine
Dobucor
Dobuject
Dobutamin
Dobutamin fresenius
Dobutamin hexal
Dobutamin ratiopharm
Dobutamin solvay
Dobutamina
Dobutamina [INN-Spanish]
Dobutamina inibsa
Dobutamina rovi
dobutamine
Dobutamine
Dobutamine (+)-isomer
Dobutamine (USP/INN)
Dobutamine [Usan:Ban:Inn]
Dobutamine [USAN:BAN:INN]
Dobutamine [Usan]
Dobutamine [USAN]
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine hydrobromide
Dobutamine hydrochloride
Dobutamine Hydrochloride
|
Dobutamine lactobionate
Dobutamine phosphate (1:1) salt, (-)-isomer
Dobutamine tartrate
Dobutamine tartrate (1:1), (R-(r*,r*))-isomer
Dobutamine tartrate (1:1), (S-(r*,r*))-isomer
Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer
dobutamine(usp)
Dobutamine, (-)-isomer
Dobutamine, phosphate (1:1) salt (+)-isomer
Dobutamin-ratiopharm
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
EINECS 277-982-4
Eli lilly brand OF dobutamine hydrochloride
Fresenius brand OF dobutamine hydrochloride
Hexal brand OF dobutamine hydrochloride
HMS2089K05
Hydrobromide, dobutamine
Hydrochloride, dobutamine
Inibsa brand OF dobutamine hydrochloride
Inotrex
Irisfarma brand OF dobutamine hydrochloride
Juste brand OF dobutamine hydrochloride
Kendrick brand OF dobutamine hydrochloride
L001157
Lactobionate, dobutamine
Lilly 81929
Lilly brand OF dobutamine hydrochloride
Lopac0_000365
LS-174467
LY 81929
NCGC00015321-05
NCGC00024629-02
NCGC00024629-03
Oxiken
Pisa brand OF dobutamine hydrochloride
Posiject
Prestwick0_000352
Prestwick1_000352
Prestwick2_000352
Prestwick3_000352
rac-dobutamine
rac-Dobutamine
racemic-dobutamine
racemic-Dobutamine
Racemic-dobutamine
Racemic-Dobutamine
Ratiopharm brand OF dobutamine hydrochloride
Rovi brand OF dobutamine hydrochloride
Solvay brand OF dobutamine hydrochloride
SPBio_002364
Tartrate, dobutamine
UNII-0WR771DJXV
UNII-3S12J47372
|
|
5 |
|
Epinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4 |
5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenalin
(−)-adrenaline
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(−)-adrenaline
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51028-73-0
51-43-4
51-43-4 (FREE BASE)
A0173
AC-13188
AC1L1L7B
Acetate, epinephrine
Adnephrine
ADR ADRENALINE
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalina
Adrenalina [DCIT]
adrenaline
Adrenaline
Adrénaline
Adrenaline (JP15)
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline/Epinephrine
Adrenalin-Medihaler
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
ADROP
AI3-19015
Allergan brand OF adrenaline hydrochloride
Ana-Guard
Ana-kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthmahaler Mist
Asthmanefrin
Asthma-nefrin
Astmahalin
Astminhal
Auvi-Q
Balmadren
Bernarenin
BIDD:GT0119
Biorenine
bmse000316
Bosmin
Brevirenin
Bronkaid
Bronkaid mist
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
Chelafrin
CHEMBL679
CID5816
Citanest Forte
Corisol
D00095
d-Adrenaline
DB00668
D-Epifrin
D-Epinephrine
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
epinephrine
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine acetate
Epinephrine bitartrate
Epinephrine hydrochloride
Epinephrine hydrogen tartrate
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
EPIPEN E Z PEN
Epipen EZ Pen
Epipen JR
EPIPEN JR
|
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
HSCI1_000215
HSDB 4289
Hypernephrin
Hyporenin
Intranefrin
Iontocaine
IOP
Isoptoepinal
Kidoline
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
l-Epinephine
L-epinephrine
L-Epinephrine
l-Epinephrine (synthetic)
l-Epirenamine
L-Epirenamine
Levoadrenaline
Levoepinephrine
Levo-Methylaminoethanolcatechol
Levorenen
Levorenin
Levorenine
Levoreninum
l-Methylaminoethanolcatechol
L-Methylaminoethanolcatechol
Lopac-E-4642
LS-156
Lyodrin
Lyophrin
Medihaler-epi
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
nchembio747-comp9
Nephridine
Nieraline
NSC 62786
NSC62786
Paranephrin
PDSP1_001120
PDSP2_001104
Primatene
Primatene mist
Primatene Mist
R-(-)-Epinephrine
Racemic Epinephrine
Racepinephrine
R-Adrenaline
RCRA waste no. P042
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
Scurenaline
Septocaine
Simplene
Sindrenina
SMP1_000227
Soladren
Sphygmogenin
ST069368
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Susphrine
Sus-phrine
Sus-Phrine
SUS-PHRINE SULFITE-FREE
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
|
|
6 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
7 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
8 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
9 |
|
Cardiotonic Agents |
|
Phase 4 |
|
|
|
10 |
|
Protective Agents |
|
Phase 4 |
|
|
|
11 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
13 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
15 |
|
Mydriatics |
|
Phase 4 |
|
|
|
16 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
17 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
18 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
19 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
20 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
21 |
|
Heparin |
Approved, Investigational |
Phase 3 |
|
9005-49-6 |
772 9812414 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
22 |
|
Zinc sulfate |
Approved, Investigational |
Phase 3 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
23 |
|
Zinc |
Approved, Investigational |
Phase 3 |
|
7440-66-6 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
24 |
|
Fluorouracil |
Approved |
Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
|
Fluorouracile [DCIT]
Fluorouracile dakota
Fluorouracile Dakota
Fluoro-uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
Fluorouracilo ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
Haemato brand OF fluorouracil
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
25 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 498142 38904 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
26 |
|
Hemostatics |
|
Phase 3 |
|
|
|
27 |
|
Tolonium Chloride |
|
Phase 3 |
|
|
|
28 |
|
Coagulants |
|
Phase 3 |
|
|
|
29 |
|
calcium heparin |
|
Phase 3 |
|
|
|
30 |
|
Trace Elements |
|
Phase 3 |
|
|
|
31 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
32 |
|
Nutrients |
|
Phase 3 |
|
|
|
33 |
|
Micronutrients |
|
Phase 3 |
|
|
|
34 |
|
Erlotinib Hydrochloride |
|
Phase 3 |
|
183319-69-9 |
176871 |
Synonyms:
|
35 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
36 |
|
Raspberry |
Approved |
Phase 1, Phase 2 |
|
|
|
37 |
|
Orange |
Approved |
Phase 1, Phase 2 |
|
|
|
38 |
|
Aminolevulinic acid |
Approved |
Phase 1, Phase 2 |
|
106-60-5 |
137 |
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5 Aminolaevulinate
5 Aminolevulinate
5451-09-2
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-amino-levulinate
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
AC-054
AC1L18K9
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
ácido 5-aminolevulínico
AKOS003587520
Aladerm
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
D07567
dALA
DALA
|
DB00855
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-aminolevulinic acid
delta-Aminolevulinic acid
DivK1c_006954
EINECS 203-414-1
Hydrochloride, aminolevulinic acid
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
Levulan
Levulinic acid, 5-amino- (8CI)
LMFA01100055
LS-101793
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
SpecPlus_000858
Spectrum_001582
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
ST50819610
UNII-88755TAZ87
δ-ALA
Δ-ala
Δ-aminolevulinate
δ-aminolevulinic acid
Δ-aminolevulinic acid
|
|
39 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
56842117 2333 |
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
|
|
40 |
|
Hydroxyurea |
Approved |
Phase 1, Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
127-07-1
1-HYDROXYUREA
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
BRN 1741548
BSPBio_002164
C07044
carbamide oxide
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroxamic Acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroximic Acid
Carbamohydroxyamic acid
Carbamohydroxyamic Acid
Carbamoyl oxime
Carbamoyl Oxime
Carbamyl hydroxamate
Carbamyl Hydroxamate
Carbamyl hydroxamic acid
Carrbamoyl Oxime
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
D00341
D006918
DB01005
DivK1c_000556
DRG-0253
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
Hydrea
Hydrea (TM)
HYDREA (TN)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
hydroxyaminomethanamide
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
hydroxyurea
Hydroxyurea
HYDROXY-UREA
Hydroxyurea (D4)
|
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [Dcit]
Idrossicarbamide [DCIT]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
Litaler
Litalir
Lopac0_000596
Lopac-H-8627
LS-709
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
NCI C04831
NCI60_002773
NCI-C04831
NCIMech_000139
NHY
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
N-HYDROXYUREA
NINDS_000556
NSC 32065
NSC32065
Oncocarbide
Onco-carbide
Onco-Carbide
Oxyurea
S1896_Selleck
Siklos
SK 22591
SMR000059149
SPBio_000247
Spectrum_000909
SPECTRUM1500344
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
S-phase/G-1 interface inhibitor
SQ 1089
SQ-1089
Sterile Urea
tetratogen: inhibits ribonucleoside diphosphate reductase
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
|
|
41 |
|
Metformin |
Approved |
Phase 2 |
|
657-24-9 |
14219 4091 |
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
42 |
|
Eniluracil |
Investigational |
Phase 1, Phase 2 |
|
59989-18-3 |
|
Synonyms:
|
43 |
|
Plasminogen |
|
Phase 2 |
|
|
|
44 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
45 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
46 |
|
Cyclooxygenase Inhibitors |
|
Phase 2 |
|
|
|
47 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
48 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 2 |
|
|
|
49 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
50 |
|
Analgesics |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 120)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial |
Unknown status |
NCT03684707 |
Phase 4 |
Metformin Hcl 500Mg 24Hr Sa Tab |
2 |
An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study |
Completed |
NCT01418118 |
Phase 4 |
Epinephrine;Norepinephrine;Dobutamine;Dopexamine |
3 |
The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor |
Recruiting |
NCT03017053 |
Phase 4 |
|
4 |
Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS |
Unknown status |
NCT01039298 |
Phase 3 |
|
5 |
Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. |
Unknown status |
NCT00655421 |
Phase 3 |
|
6 |
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) |
Unknown status |
NCT03685409 |
Phase 3 |
Metformin Hydrochloride 500 MG;Placebo Oral Tablet |
7 |
Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158678 |
Phase 3 |
concomitant cisplatin |
8 |
Efficacy of Zinc Sulfate on Concurrent Chemoradiotherapy Induced Taste Alterations in Oral Cancer Patients- A Double Blind Randomized Controlled Trial |
Completed |
NCT03824925 |
Phase 3 |
Placebo oral Zinc capsule;Zinc Sulfate 220 MG |
9 |
Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158652 |
Phase 3 |
5FU, Paraplatin |
10 |
Erlotinib Prevention of Oral Cancer (EPOC) |
Completed |
NCT00402779 |
Phase 3 |
Erlotinib;Placebo |
11 |
Workplace Tobacco Cessation And Oral Cancer Screening Study |
Completed |
NCT00750503 |
Phase 3 |
|
12 |
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial |
Recruiting |
NCT04713449 |
Phase 3 |
|
13 |
Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) |
Terminated |
NCT00537199 |
Phase 3 |
OraTest |
14 |
Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer |
Unknown status |
NCT02960724 |
Phase 2 |
|
15 |
Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral |
Unknown status |
NCT03008694 |
Phase 2 |
|
16 |
Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer |
Unknown status |
NCT02739204 |
Phase 2 |
Celecoxib |
17 |
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer |
Completed |
NCT01469429 |
Phase 1, Phase 2 |
chemoprevention;chemoprevention |
18 |
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx |
Completed |
NCT03515538 |
Phase 2 |
RRx-001;Cisplatin for injection |
19 |
A Study of the Effects of PEITC on Oral Cells With Mutant p53 |
Completed |
NCT01790204 |
Phase 1, Phase 2 |
|
20 |
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral |
Completed |
NCT03638622 |
Phase 1, Phase 2 |
|
21 |
A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) |
Completed |
NCT00933387 |
Phase 2 |
Cetuximab,Paclitaxel,Cisplatin |
22 |
Efficacy of Implant-Supported Maxillofacial Prostheses |
Completed |
NCT00006341 |
Phase 2 |
|
23 |
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention |
Completed |
NCT01192204 |
Phase 1, Phase 2 |
10% FBR containing bioadhesive gel;placebo gel |
24 |
A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer |
Completed |
NCT00004901 |
Phase 1, Phase 2 |
ethynyluracil;fluorouracil;hydroxyurea |
25 |
M4OC-Prevent: Metformin for Oral Cancer Prevention |
Active, not recruiting |
NCT02581137 |
Phase 2 |
Metformin Hydrochloride |
26 |
Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy |
Not yet recruiting |
NCT04251949 |
Phase 2 |
|
27 |
Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging |
Not yet recruiting |
NCT04191460 |
Phase 2 |
cRGD-ZW800-1. |
28 |
Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions |
Completed |
NCT01604759 |
Phase 1 |
|
29 |
Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial |
Recruiting |
NCT04473716 |
Phase 1 |
Toripalimab;Paclitaxcel;Cisplatin |
30 |
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial |
Recruiting |
NCT04393506 |
Phase 1 |
Camrelizumab;Apatinib |
31 |
"Safety and Tolerability of Neoadjuvant Nivolumab for Locally Advanced Resectable Oral Cancer Combined With [18F] BMS-986192 / [18F] -FDG PET Imaging and Immunomonitoring for Response Prediction" |
Recruiting |
NCT03843515 |
Phase 1 |
Nivolumab |
32 |
PK Analysis of Antitumor B in Patients With Oral Cancer |
Not yet recruiting |
NCT03459729 |
Phase 1 |
Antitumor B |
33 |
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer |
Withdrawn |
NCT02251639 |
Phase 1 |
|
34 |
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma |
Unknown status |
NCT00173849 |
|
|
35 |
Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers |
Unknown status |
NCT00154973 |
|
|
36 |
Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled |
Unknown status |
NCT00765791 |
Early Phase 1 |
|
37 |
Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography |
Unknown status |
NCT00172965 |
|
|
38 |
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line: In Vitro Study |
Unknown status |
NCT03288298 |
Early Phase 1 |
luteolin;nano-luteolin |
39 |
Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor. |
Unknown status |
NCT01919567 |
|
|
40 |
Observational Study on the Carcinogenesis of Gα12 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using Ga12 Inhibitor. |
Unknown status |
NCT01919580 |
|
|
41 |
Elective Versus Therapeutic Neck Dissection in the Treatment of Early Node Negative Squamous Cell Carcinoma of the Oral Cavity |
Unknown status |
NCT00193765 |
|
|
42 |
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis |
Unknown status |
NCT00173381 |
|
|
43 |
The Role of Vascular Endothelial Growth Factor-C (VEGF-C) and Its Receptors Induced Lymphangiogenesis on the Carcinogenesis of Oral Cancers and Premalignant Lesions |
Unknown status |
NCT00173316 |
|
|
44 |
Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer |
Unknown status |
NCT01136265 |
|
|
45 |
The Role of microRNA-29b in the Oral Squamous Cell Carcinoma |
Unknown status |
NCT02009852 |
|
|
46 |
Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study |
Unknown status |
NCT02866500 |
|
|
47 |
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Early Stages Oral and Oropharyngeal Squamous Cell Carcinomas: A Prospective Study |
Unknown status |
NCT00232960 |
|
|
48 |
The Relation of Microtubule-Associated Protein 2 and Cell Migration |
Unknown status |
NCT00174109 |
|
|
49 |
Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study |
Unknown status |
NCT02902406 |
|
|
50 |
A Prospective, Randomized, Clinical Study to Evaluate the Effects of Early Enteral Nutritional Supplementation on Clinical Outcomes in Patients With Oral Cancer Undergoing Radio(Chemo)Therapy After Surgical Resection |
Unknown status |
NCT03545490 |
|
|
|